An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

被引:106
作者
Fauvel, J
Bonnet, E
Ruidavets, JB
Ferrières, J
Toffoletti, A
Massip, P
Chap, H
Perret, B
机构
[1] Toulouse Univ Hosp, Lab Biochim 3, Toulouse, France
[2] Toulouse Univ Hosp, INSERM, U326, IFR 30,Inst Claude Preval, Toulouse, France
[3] Toulouse Univ Hosp, Serv Malad Infect, Toulouse, France
[4] Toulouse Univ Hosp, INSERM, U558, Toulouse, France
关键词
protease inhibitor; dyslipidaemia; apolipoprotein C-III; polymorphism; lipoparticle;
D O I
10.1097/00002030-200112070-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Long-term therapy with protease inhibitors (PI) is associated with hypertriglyceridaemia, low high-density lipoprotein (HDL) levels and accumulation of apolipoprotein (apo) E- and apo C-III-containing lipoproteins. Objectives: To evaluate the impact, on this dyslipaemic phenotype, of three polymorphisms of the apo C-III gene: two on an insulin response element and one in the 3'-region. Apo E genotypes were evaluated also. Design: Sixty consecutive male patients attending the HIV follow-up consultation were included during a 3-month period. All patients received at least one PI. Apo C-III and apo E genotypes were determined. Besides routine bio-clinical examination, a detailed exploration of lipoproteins and of insulin secretion markers was carried out. Methods: Plasma lipoparticles, insulin, proinsulin and C-peptide were measured by specific immuno-assays. Determination of apo C-III genotypes (-455C/T, -482C/F and Sstl) and of apo E alleles (epsilon2, epsilon3 and epsilon4) were performed by amplification and endonuclease digestion and were confirmed by allele-specific oligonucleotide hybridization. Results: Distribution of apo C-III alleles defined four major haplotyes. Carriers of the -455C variant had 30% lower levels of HDL-cholesterol than non-carriers. Plasma triglycerides increased according to the number of variant alleles. in multivariate analysis, a model including age, body mass index, clinical stage and treatment length, plasma insulin and apo C-III haplotypes explained around 43% of the HDL-cholesterol and triglycerides variability, Measurements of lipids before and after the use of PI demonstrated synergistic effects of the treatment and apo C-III variants on triglyceride levels. Conclusions: Apo C-III polymorphisms might identify a genetic predisposition to develop dyslipidaemia under PI therapy. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:2397 / 2406
页数:10
相关论文
共 47 条
[11]   MODULATION OF LIPOPROTEIN B BINDING TO THE LDL RECEPTOR BY EXOGENOUS LIPIDS AND APOLIPOPROTEIN-CI, APOLIPOPROTEIN-CII, APOLIPOPROTEIN-CIII, AND APOLIPOPROTEIN-E [J].
CLAVEY, V ;
LESTAVELDELATTRE, S ;
COPIN, C ;
BARD, JM ;
FRUCHART, JC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (07) :963-971
[12]   Gender related association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France [J].
Dallongeville, J ;
Meirhaeghe, A ;
Cottel, D ;
Fruchart, JC ;
Amouyel, P ;
Helbecque, N .
ATHEROSCLEROSIS, 2000, 150 (01) :149-157
[13]   AN APOLIPOPROTEIN CIII HAPLOTYPE PROTECTIVE AGAINST HYPERTRIGLYCERIDEMIA IS SPECIFIED BY PROMOTER AND 3' UNTRANSLATED REGION POLYMORPHISMS [J].
DAMMERMAN, M ;
SANDKUIJL, LA ;
HALAAS, JL ;
CHUNG, W ;
BRESLOW, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (10) :4562-4566
[14]  
DECKELBAUM RJ, 1979, J BIOL CHEM, V254, P6079
[15]   Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors [J].
Dowell, P ;
Flexner, C ;
Kwiterovich, PO ;
Lanes, MD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (52) :41325-41332
[16]   ABNORMALITIES IN VERY LOW, LOW, AND HIGH-DENSITY LIPOPROTEINS IN HYPERTRIGLYCERIDEMIA - REVERSAL TOWARD NORMAL WITH BEZAFIBRATE TREATMENT [J].
EISENBERG, S ;
GAVISH, D ;
OSCHRY, Y ;
FAINARU, M ;
DECKELBAUM, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (02) :470-482
[17]  
EISENBERG S, 1979, J BIOL CHEM, V254, P2603
[18]   TRENDS IN ACUTE MYOCARDIAL-INFARCTION PROGNOSIS AND TREATMENT IN SOUTHWESTERN FRANCE BETWEEN 1985 AND 1990 (THE MONICA PROJECT-TOULOUSE) [J].
FERRIERES, J ;
CAMBOU, JP ;
RUIDAVETS, JB ;
POUS, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (17) :1202-1205
[19]  
Groenendijk M, 1999, J LIPID RES, V40, P1036
[20]   Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins [J].
Hegele, RA ;
Connelly, PW ;
Hanley, AJG ;
Sun, F ;
Harris, SB ;
Zinman, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2753-2758